Cardiac Health

Improving Cardiac Health Through Early Detection

Cardiovascular disease is the leading cause of death worldwide. Unquestionably, the best possible treatment begins with early detection. Without formal cardiac health screening guidelines, clinicians must leverage opportunities for incidental detection of cardiac health biomarkers. Learn more about coronary artery calcification, a strong predictor of future cardiac events, and how to detect it.

A smiling middle-aged man wearing casual clothing with an anatomical heart overlay on his chest, symbolizing Riverain Technologies' coronary artery calcium scoring capabilities.

Why is Early Detection Important?

Coronary artery calcification is scored using a CT and is shown to assess cardiovascular risk.
An estimated 24 million Americans have moderate to severe CAC.¹
Many patients with moderate and severe levels of CAC go undetected, missing the opportunity for effective, early interventions.

Quantifying CAC for Those At-Risk

For patients with symptoms, CAC is scored through a specific type of cardiac CT exam to calculate an Agatston score that is used to quantify the amount of CAC and cardiac risk.
CAC can be scored on non-cardiac CT exams but over half of incidental findings are not reported.
30% of patients enrolled in low-dose CT lung cancer screening programs have high CAC scores.²

A Population Health Approach to Cardiac Risk

When battling the leading cause of death worldwide, clinicians need the most effective and scalable tools available to maximize the benefit of early detection of coronary artery calcification (CAC). ClearRead (TM) Chest is a comprehensive AI suite that provides accurate detection and analysis of pulmonary nodules, coronary artery calcification scoring, and quantification of hypodense lung tissue. ClearRead gives clinicians the tools and information they need to make informed decisions about the one of most prevalent and dangerous cardiac conditions.

ClearRead CT is a valuable addition to a lung cancer screening program or as a standalone solution to incidental CAC scoring and cardiac risk assessment.

Original unprocessed axial chest CT scan at lung window demonstrating standard radiological appearance before ClearRead CT AI-powered image enhancement processing.

Learn More

AI Advantages for Cardiac Health

Opportunistic Screening for CAC

Dr. James Hillis, Director of Clinical Operations at Mass General Brigham AI speaks to Brian Casey of the Imaging Wire at RSNA 2025 in the Riverain Technologies booth.

¹https://www.acc.org/latest-in-cardiology/articles/2024/03/08/14/10/navigating-cv-risk-assessment-in-older-patients
²https://www.cmaj.ca/content/196/41/E1362

Contact us

Thank you for your interest in Riverain Technologies. Whether you’d like to arrange a demo, create a service request, or simply share a question or concern with our team, please contact us. We’re ready to help.